"
Team:Lethbridge Canada/Results
From 2012hs.igem.org
(Difference between revisions)
(→Results) |
(→Results) |
||
| Line 32: | Line 32: | ||
| - | <table><table border="3"> | + | <div align="center"><table><table border="3"> |
<tr><td><b>Name</b></td><td><b>Type</b></td><td><b>Description</b></td><td><b>Length</b></td></tr> | <tr><td><b>Name</b></td><td><b>Type</b></td><td><b>Description</b></td><td><b>Length</b></td></tr> | ||
<tr><td>[http://partsregistry.org/Part:BBa_K736000 BBa_K736000]</td><td>Regulatory</td><td>Constitutive Promoter (J23100) with MLC (glucose-regulated) binding site</td><td>36 bp</td></tr> | <tr><td>[http://partsregistry.org/Part:BBa_K736000 BBa_K736000]</td><td>Regulatory</td><td>Constitutive Promoter (J23100) with MLC (glucose-regulated) binding site</td><td>36 bp</td></tr> | ||
| Line 38: | Line 38: | ||
<tr><td>[http://partsregistry.org/Part:BBa_K736002 BBa_K736002]</td><td>Composite</td><td>Constitutive Promoter with MLC-binding-site-regulated enhanced RFP</td><td>913 bp</td></tr> | <tr><td>[http://partsregistry.org/Part:BBa_K736002 BBa_K736002]</td><td>Composite</td><td>Constitutive Promoter with MLC-binding-site-regulated enhanced RFP</td><td>913 bp</td></tr> | ||
<tr><td>[http://partsregistry.org/Part:BBa_K736003 BBa_K736003]</td><td>Composite</td><td>pLAC-regulated TAT-RFP construct</td><td>948 bp</td></tr> | <tr><td>[http://partsregistry.org/Part:BBa_K736003 BBa_K736003]</td><td>Composite</td><td>pLAC-regulated TAT-RFP construct</td><td>948 bp</td></tr> | ||
| - | </table><br /> | + | </table><br/> |
<html> | <html> | ||
<head> | <head> | ||
</html> | </html> | ||
Revision as of 01:46, 17 June 2012
 |
|---|
| Home | The Team | The Project | Results | Human Practices | Notebook | Safety |
|---|
ResultsWe created two new parts, [http://partsregistry.org/Part:BBa_K736000 BBa_K736000] (which regulated the transcription of downstream genes) and [http://partsregistry.org/Part:BBa_K736001 BBa_K736001] (which was a TAT signal sequence fused to a red fluorescent protein (E1010).
|
